Cancer immunotherapy using checkpoint blockade

4.6kCitations
Citations of this article
3.5kReaders
Mendeley users who have this article in their library.
Get full text

Abstract

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination. The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints. Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse. Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-g signaling pathways. New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.

Cite

CITATION STYLE

APA

Ribas, A., & Wolchok, J. D. (2018, March 23). Cancer immunotherapy using checkpoint blockade. Science. American Association for the Advancement of Science. https://doi.org/10.1126/science.aar4060

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free